A favourable safety profile, with no hair loss

Xeloda^© monotherapy is well tolerated. The majority of treatment-related adverse events are mild or moderate in intensity and grade 3/4 adverse events occur infrequently.

Myelosuppression and alopecia are rare in patients taking Xeloda^© monotherapy. The safety profile of oral Xeloda^© is otherwise typical of infused fluoropyrimidines.

The incidence of treatment-related grade 3/4 adverse events has been evaluated from the pooled data of 875 patients in phase II clinical trials.¹

The most frequent treatment-related adverse events that may occur with Xeloda^© include hand–foot syndrome, diarrhoea, abdominal pain, nausea, vomiting and stomatitis.

Adverse events due to Xeloda^© administration may be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction).